202
X. Yao et al. / Tetrahedron: Asymmetry 12 (2001) 197–204
crude solid was redissolved in 20 mL CH2Cl2, washed
with water (2×10 mL) and brine (15 mL). After drying
over Na2SO4, the solvent was removed under vacuum,
and the product was isolated as a yellow powder.
(s, 2H), 7.37 (d, J=2.0 Hz, 2H), 7.06 (d, J=2.0 Hz,
2H), 3.34–3.32 (m, 2H), 2.0–1.4 (m, 8H), 1.23 (s, 18H);
13C NMR: 164.6, 154.9, 141.8, 130.0, 126.6, 120.8,
118.5, 72.4, 34.0, 33.0, 31.2, 24.0.
4.1.1. (R,R)-N,N%-Bis(3,5-di-tert-butyl-salicylidene)-1,2-
cyclohexanediamine 1a. Mp 202–203°C; [h]2D0=−309 (c
4.1.9.
(R,R)-N,N%-Bis(3,5-di-chloro-salicylidene)-1,2-
cyclohexanediamine 1i. Mp 139–141°C; [h]2D0=−371 (c 1,
1
1
1, CH2Cl2); H NMR (DCCl3) l 13.77 (s, 2H), 8.34 (s,
CH2Cl2); H NMR (DCCl3) l 14.20 (s, 2H), 8.18 (s,
2H), 7.34 (d, J=2.2 Hz, 2H), 7.02 (d, J=2.2 Hz, 2H),
3.70–3.30 (m, 2H), 2.0–1.4 (m, 8H), 1.44 (s, 18H), 1.27
(s, 18H); 13C NMR: 165.9, 158.1, 139.9, 136.4, 126.8,
117.9, 72.4, 35.0, 34.1, 33.3, 29.5, 24.4.
2H), 7.34 (s, 2H), 7.07 (s, 2H), 3.37–3.33 (m, 2H),
2.0–1.4 (m, 8H); 13C NMR: 163.3, 156.2, 132.2, 129.1,
122.8, 122.5, 119.1, 72.1, 32.8, 23.8.
4.1.10. (R,R)-N,N%-Bis(5-chloro-salicylidene)-1,2-cyclo-
hexanediamine 1j. Mp 191°C; [h]2D0=−199 (c 1, CH2Cl2);
1H NMR (DCCl3) l 13.22 (s, 2H), 8.14 (s, 2H), 7.17
(dd, J=2.3 Hz, 8.8 Hz, 2H), 7.09 (d, J=1.4 Hz, 2H),
6.83 (d, J=8.8 Hz, 2H), 3.30–3.24 (m, 2H), 1.9–1.4 (m,
8H); 13C NMR: 163.5, 159.4, 132.0, 130.4, 123.1, 119.2,
118.3, 72.5, 32.8, 23.9.
4.1.2.
(R,R)-N,N%-Bis-salicylidene-1,2-cyclohexanedi-
1
amine 1b. Mp 59–60°C; [h]2D0=−394 (c 1, CH2Cl2); H
NMR (DCCl3) l 13.02 (s, 2H), 8.24 (s, 2H), 7.24–7.20
(m, 2H), 7.13 (dd, J=1.6 Hz, 7.7 Hz, 2H), 6.88 (d,
J=8.2 Hz, 2H), 6.89–6.76 (m, 2H), 3.30–3.28 (m, 2H),
1.9–1.4 (m, 8H); 13C NMR: 164.6, 160.9, 132.1, 131.4,
118.5, 116.7, 72.5, 33.0, 24.1.
4.1.11. (R,R)-N,N%-Bis(3-nitro-5-tert-butyl-salicylidene)-
1,2-cyclohexanediamine 1k. Mp 105–106°C; [h]2D0=−566
4.1.3.
(R,R)-N,N%-Bis(3,5-di-methyl-salicylidene)-1,2-
1
cyclohexanediamine 1c. Mp 105–107°C; [h]2D0=−384 (c
(c 1, CH2Cl2); H NMR (DCCl3) l 15.10 (s, 2H), 8.38
1
1, CH2Cl2); H NMR (DCCl3) l 13.38 (s, 1H), 8.18 (s,
(s, 2H), 8.05 (d, J=2.4 Hz, 2H), 7.46 (d, J=2.4 Hz,
2H), 3.48–3.41 (m, 2H), 2.0–1.4 (m, 8H) 1.27 (s, 18H);
13C NMR: 164.9, 155.8, 140.3, 137.4, 134.4, 126.6,
119.8, 71.5, 34.1, 32.8, 30.9, 23.9.
1H), 6.92 (s, 2H), 6.77 (s, 2H), 3.28–3.25 (m, 2H), 2.20
(s, 6H), 2.17 (s, 6H), 1.9–1.4 (m, 8H); 13C NMR: 164.7,
156.9, 134.1, 129.1, 126.9, 125.2, 117.5, 72.6, 33.1, 24.1,
20.2, 15.3.
4.1.12. Preparation of (R,R)-N,N%-bis(3,5-di-nitro-sali-
cylidene)-1,2-cyclohexanediamine 1l. In a 50 mL Schlenk
flask, (R,R)-1,2-diammoniumcyclohexane (1 mmol) was
dissolved in ethanol (10 mL). The solution was heated
under reflux, and a solution of 3,5-dinitrosalicylalde-
hyde (2 mmol) in ethanol (10 mL) was added over a
period of 30 minutes; the reaction mixture was then
stirred under reflux for 2 hours. The mixture was
cooled to room temperature. The crystalline product
was collected and washed with ethanol (5 mL) and
diethyl ether (5 mL), affording product 1l as orange
crystalline powder (85% yield). Mp 248–249°C; [h]2D0=
4.1.4.
(R,R)-N,N%-Bis(5-tert-butyl-salicylidene)-1,2-
cyclohexanediamine 1d. Mp 116–118°C; [h]2D0=−179 (c
1
1, CH2Cl2); H NMR (DCCl3) l 13.14 (s, 2H), 8.26 (s,
2H), 7.27 (dd, J=1.3 Hz, 8.7 Hz, 2H), 7.12 (s, 2H), 6.82
(d, J=8.7 Hz, 2H), 3.30–3.28 (m, 2H), 1.9–1.4 (m, 8H),
1.23 (s, 18H); 13C NMR: 164.9, 158.6, 141.1, 129.4,
127.9, 117.9, 116.2, 72.7, 33.8, 33.1, 31.3, 24.1.
4.1.5. (R,R)-N,N%-Bis(3-bromo-5-tert-butyl-salicylidene)-
1,2-cyclohexanediamine 1e. Mp 197–200°C; [h]2D0=−309
(c 1, CH2Cl2); H NMR (DCCl3) l 14.17 (s, 2H), 8.22
(s, 2H), 7.53 (s, 2H), 7.10 (d, J=1.3 Hz, 2H), 3.34–3.29
(m, 2H), 1.9–1.4 (m, 8H), 1.25 (s, 18H); 13C NMR:
164.5, 155.8, 142.3, 132.9, 127.4, 118.3, 110.6, 72.2,
34.0, 32.9, 31.2, 24.0.
1
1
−148 (c 1, DMSO); H NMR (DMSO-d6) l 13.56 (s,
2H), 8.92 (s, 2H), 8.76 (d, J=3.42 Hz, 2H), 8.66 (d,
J=3.42 Hz, 2H), 4.26–4.24 (m, 2H), 2.1–1.0 (m, 8H);
13C NMR: 169.7, 167.7, 140.7, 137.6, 129.9, 127.5,
117.2, 63.3, 30.7, 23.4.
4.1.6.
(R,R)-N,N%-Bis(3,5-di-bromo-salicylidene)-1,2-
cyclohexanediamine 1f. Mp 140–142°C; [h]2D0=−267 (c
4.1.13.
(R,R)-N,N%-Bis(5-nitro-salicylidene)-1,2-cyclo-
1
1, CH2Cl2); H NMR (DCCl3) l 14.32 (s, 2H), 8.14 (s,
hexanediamine 1m. Mp 219–221°C; [h]2D0=−20.9 (c 1,
1
2H), 7.64 (s, 2H), 7.24 (s, 2H), 3.37–3.35 (m, 2H),
2.0–1.4 (m, 8H); 13C NMR: 163.2, 157.8, 137.7, 132.9,
119.6, 112.1, 109.7, 71.9, 32.8, 23.8, 18.4.
CH2Cl2); H NMR (DCCl3) l 14.32 (s, 2H), 8.36 (s,
2H), 8.15–8.12 (m, 4H), 6.93 (d, J=8.9 Hz, 2H), 3.52–
3.45 (m, 2H), 2.05–1.50 (m, 8H); 13C NMR: 167.5,
163.7, 139.3, 128.0, 127.9, 118.3, 117.0, 71.7, 32.6, 23.8.
Anal. calcd for C20H20N4O6: C, 58.25; H, 4.89; N,
13.59; O, 23.58. Found: C, 58.53; H, 4.96; N, 13.77%.
4.1.7. (R,R)-N,N%-Bis(5-bromo-salicylidene)-1,2-cyclo-
hexanediamine 1g. Mp 189–190°C; [h]2D0=−99 (c 1,
CH2Cl2); H NMR (DCCl3) l 13.24 (s, 2H), 8.15 (s,
1
2H), 7.31 (dd, J=2.2 Hz, 8.8 Hz, 2H), 7.25 (d, J=8.8
Hz, 2H), 6.79 (d, 2H), 3.30–3.28 (m, 2H), 1.9–1.4 (m,
8H); 13C NMR: 163.4, 159.9, 134.9, 133.4, 119.8, 118.8,
110.0, 72.5, 32.8, 24.0.
4.2. Preparation of catalyst 2
In a 50 mL Schlenk flask, Ru(PPh3)Cl2 (0.2206 g, 0.230
mmol) was mixed with the ligand 1m (0.1000 g, 0.242
mmol) in iso-propanol (15 mL); Et3N (0.192 mL, 6
equiv.) was then added. The solution was stirred under
reflux for two hours, then cooled to room temperature.
The crystalline product was collected and recrystallized
4.1.8. (R,R)-N,N%-Bis(3-chloro-5-tert-butyl-salicylidene)-
1,2-cyclohexanediamine 1h. Mp 209–212°C; [h]2D0=−266
1
(c 1, CH2Cl2); H NMR (DCCl3) l 14.14 (s, 2H), 8.25